Haematopoietic stem cell transplantation (HSCT) remains the only cure for most haematological malignancies, however, the mortality rate remains high. Complications after HSCT include relapse, graft versus host disease (GvHD), graft rejection and infection. Over the last few years several groups, have demonstrated that non-HLA gene polymorphisms can be predictive of outcome after HSCT. Since the glucocorticoid cortisol is pivotal in the regulation of the immune system, we decided to examine single nucleotide polymorphisms (SNPs; rs6198, rs33388 and rs33389) within the glucocorticoid receptor (GR) and correlate with HSCT outcome. The training set consisted of patients (n = 458) who underwent HSCT for acute leukaemia between 1983 and 2005. In the recipients, the absence of the ACT haplotype and absence of the T allele of rs33388 were associated with decreased OS and the absence of the ACT haplotype, the absence of the T allele of rs33388 and the presence of the ATA haplotype were associated with increased risk of relapse. In addition, the presence of the ACT haplotype in the recipient showed a trend to be associated with increased risk of chronic graft versus host disease (cGvHD). The patients in this cohort received mainly myeloablative conditioning (n = 327). The SNPs in the glucocorticoid receptor were then investigated in a validation set (n = 251) of HSCT patients transplanted for acute leukaemia from 2006. This cohort contained significantly more patients that had received reduced intensity conditioning (RIC). Some of the results could be validated in these patients. However, contrary to the training set, the absence of the haplotype ACT in the donor in this cohort was associated with increased risk of cGvHD. Differences in the conditioning were shown to influence the results. These results are the first to associate GR SNPs with HSCT outcome and demonstrate the inherent problems of replicating SNP association studies in HSCT, due to different pre-transplant regimens.
| INTRODUC TI ON
Glucocorticoids such as cortisol are involved in the regulation of the immune system and inflammation, Rhen and Cidlowski (2005) and exert their effect through binding to the glucocorticoid receptor (GR), (HUGO gene nomenclature NR3C1), a transcription factor expressed in most cells. This receptor binds glucocorticoids in the cytoplasm and translocates them to the nucleus, where they influence the expression of many genes, chiefly by interfering with the binding of transcription factor activating protein and nuclear factor κβ to inflammatory immune genes such as interleukin (IL) IL-1, IL-2, IL-3, IL-6, IL-8, and TNFα and causing their down regulation, Chikanza, Kozaci, and Chernajovsky (2003) . Glucocorticoids can also induce the transcription of anti-inflammatory genes including IL-4, IL-10, IL-13 and transforming growth factor β (TGFβ), Chikanza et al. (2003) .
The human glucocorticoid receptor gene contains 10 exons and has two main isoforms, GR-α and GR-β which are generated as a result of alternative splicing, Castro et al. (1996) , Encio and DeteraWadleigh (1991) as can be seen in figure 1. Both isoforms share exons 1-8; for the GR-α isoform, exons 1-9α are transcribed into GRα mRNA, the functional GR receptor. In the case of the GR-β isoform, exon 9a is replaced with exon 9b, resulting in GR-β mRNA.
GR-β does not itself bind hormone, but is thought to have an antagonistic effect on GR-α signalling by heterodimerization with GR-α Castro et al. (1996) , Encio and Detera-Wadleigh (1991) . Associations have been reported between GR-β over expression and autoimmune disease and inflammation, Derijk et al. (2001) , Chatzikyriakidou et al. (2009) , and Van den Akker and Koper (2008) but it is not clear whether this is actually a cause or an effect and whether this increase in GR-β is enough to have an effect on the activity of GR-α.
The single nucleotide polymorphism (SNP) rs6198 is situated in the 3′ UTR of exon 9β of the GR gene and changes a consensus sequence from ATTTA to GTTTA. The ATTTA sequence is known to destabilize GR-βmRNA, Derijk et al. (2001) . The A to G substitution therefore increases the stability of the GR-β mRNA, so this G allele is thought to be the GC resistant allele, as more GR-β is available to bind to GR-α which in turn gives less cortisol induced immunosuppression.
The G allele of rs6198 has been associated with rheumatoid arthritis (RA), Derijk et al. (2001) , Chatzikyriakidou et al. (2009) , heart disease, Van den Akker et al. (2008) and reduced nasal carriage of staphylococcus aureus, Van den Akker et al. (2006) . More recently, a trend to an association has been found with the G allele of rs6198 in the patient and corticosteroid sensitive aGvHD, O'Meara et al. (2015) .
In addition, SNPs in intron B of the GR gene have been shown to predispose to RA susceptibility, Chatzikyriakidou et al. (2009) . The SNPs rs33388 (A to T substitution) and rs33389 (C to Tsubstitution) are in intron B and are in partial linkage disequilibrium. Carriage of the variant T allele of rs33388 has been positively associated with the incidence of RA (p = 0.025). The AT haplotype of rs33388 and rs33389 has also been associated with increased glucocorticoid sensitivity, Stevens et al. (2004) and it exhibits higher sensitivity to steroid treatment in children with nephritic syndrome, Zalewski, Wasilewska, Zoch-Zwierz, and Chyczewski (2008). These SNPs are thought to influence gene transcription by altering consensus recognition sites for SR proteins, Cartegni, Chew, and Krainer (2002) , which are serine arginine rich factors involved in alternative splicing of RNA. Indeed, interrogation of the splicing factor map (SFMAP) database suggests that rs33388 lies in consensus recognition sites for the RNA splicing factors, QK1 (rs33388) and SRp20, also known as SRSF3 (rs33389) and, in fact, the T allele of rs33389 is predicted to create additional QK1 and SRp20 sites. In addition, rs33388 and rs33389 have roles not only in mRNA splicing, but also in export of mRNA from the nucleus and in protein translation, Paz, Akerman, Dror, Kosti, and Mandel-Gutfreund (2010) .
We hypothesized that SNPs in the GR gene may be associated with outcome after HSCT and influence acute and chronic GvHD, relapse, NRM, and OS. We therefore examined the role of SNPs rs6198, rs33389 and rs33388 and their haplotypes on NRM, OS, 
| MATERIAL S AND ME THODS

| Patients
The training set consisted of 458 adult HLA matched sibling and HLA-matched unrelated patient and donor pairs from eight European transplant centres, where 66% had received T cell replete stem cell grafts. They were analysed retrospectively and all of the patients had undergone HSCT for acute leukaemia. Transplants were conducted between November 1983 and December 2005. Relapse was defined as haematological relapse. The main causes of death were relapse (46%), infection (21%), and GvHD (18%). The validation cohort consisted of 251 adult HLA-matched sibling and matched unrelated patient and donor pairs undergoing HSCT for acute leukaemia from January 2006 to January 2010 at four European centres. This cohort was also analysed retrospectively and the main causes of death were relapse (51.2%), GvHD (25%), and infection (14.3%). There was no overlap of patients between the cohorts. The samples from the patients and donors were obtained following informed consent and approval in accordance with EBMT guidelines and the diagnosis of GvHD was made following the standard criteria, Glucksberg et al. (1974) . The majority of the cohort after the year 2000 had high-resolution tissue typing for HLA Class I A, B, C and Class II DP, DQ and DR.
| Genotyping
DNA was prepared from archived frozen peripheral blood mononuclear cells by standard techniques, consisting of SDS lysis, proteinase K digestion, phenol chloroform extraction followed by ethanol precipitation. Genotyping for the SNPs rs6198, rs33388, and rs33389 was outsourced to Kbioscience (https://www.kbioscience.co.uk) using their own fluorescence based competitive PCR technology (KASPar). They also designed the assays for the SNPs based on the DNA sequence (50 bases) on either side of the SNP (Figure 1 ).
| Statistical analysis
The impact of the selected GR SNPs on survival was assessed via Kaplan Meier (log rank) tests and Cox regression modelling. NRM and relapse were analysed using the method of competing risks, Kaplan Meier (log rank) tests, and Cox regression modelling. As clinical data were categorical, differences between cohorts were as- 
| RE SULTS
| Clinical characteristics
| GR SNP frequencies in our cohorts
The occurrence of the variant alleles was comparable to that for published Caucasian allele frequencies for rs33388 and rs33389, but significantly different for rs6198 (all allele frequencies taken from the National centre for biotechnology information) as shown in Table 2 . This difference could be because the published cohorts were actually smaller than in our study cohort, indeed as can be seen from table 2 for rs6198 the allele frequency in our cohort falls between the two published allele frequencies for Caucasians. The SNPs are in Hardy-Weinberg equilibrium (p = >0.05) and partial linkage disequilibrium Donn, Payne, and Ray (2007) and therefore, we were also able to assign each patient or donor a specific haplotype (i.e. ACT, ATA, ACA and GCA and the SNP order for the haplotype designation is rs6198, then rs33389, then rs33388).
| Training set
None of the GR SNP variables were found to be associated with Table 3 ). The cumulative incidence plots for relapse for the recipient GR haplotype ACT and ATA, and the recipient rs33388 any T allele are shown in Figure 3a ,b,c.
None of the recipient or donor GR SNP variables were found to be associated with the incidence or severity of acute GvHD. For chronic graft versus host disease (cGvHD), there was an indication that carriage of the ACT haplotype in the recipient was associated with the incidence of chronic GvHD (p = 0.075, OR: 1.833, 95% CI: 0.966-3.478).
| Validation set
In this cohort, none of the GR SNP variables in either patients or donors were associated with NRM and OS. As in the training set, none of the donor GR SNP variables were found to be associated with relapse; in the recipient, in contrast to the training set, the presence of the ACA haplotype was associated with an increased risk of relapse (p = 0.042, HR: 1.921, 95% CI: 1.003-3.678; Table 3), the cumulative incidence plots are shown in Figure 3d .
Further differences were observed between the training and validation sets with regard to acute and chronic GvHD. Table 4 .
| Myeloablative and RIC cohorts
The two cohorts were then combined and split into two new cohorts based on the type of pre-transplant conditioning, either RIC or myeloablative, and the analysis repeated. Again none of the SNP variables in the donor or recipient were associated with NRM in either of these cohorts. In the myeloablative cohort, the new finding was that the presence of the G allele of rs6198 in the recipient was Notes. GvHD, graft versus host disease. a Cramér's V with a range from 0 to 1. For this set of results, Cramér's V statistics of 0.1, 0.3, and 0.5 are considered small, medium, and large effect sizes, respectively (Cohen, 1988) . b Nonrelapse mortality (NRM) = "Yes" defined as patient dead without ever experiencing a prior relapse; nonrelapse mortality (NRM) = "No" defined as patient alive without ever experiencing a prior relapse or patient has had a relapse.
TA B L E 1 (Continued)
TA B L E 2 Glucocorticoid receptor single nucleotide polymorphisms frequencies in our cohort 
2006-2010). As depicted in
| D ISCUSS I ON
Haematopoietic stem cell transplantation remains the main curative therapy for patients with acute leukaemia, however the mortality rate remains high (40%-60%), Bensinger and Storb (2001) . In re- The ACT haplotype contains two GC resistant alleles; the C allele of rs33389 and the T allele of rs33388 so it could be that carriage of this inflammatory haplotype might be aiding the graft versus leukaemia (GVL) effect and therefore, the absence of this haplotype would result in a more immunosuppressed phenotype giving rise to reduced OS. Indeed, when the incidence of relapse was investigated we found that for the first cohort in the recipient, the absence of the haplotype ACT, the presence of the haplotype ATA and the absence of the T allele of rs33388 was significantly associated with increased Hazard ratio = 1.597 indicates that the hazard of relapse is 1.597 times higher when the ATA haplotype is present compared to when the ATA haplotype is absent. b Hazard ratio = 0.539 indicates the hazard of relapse is lower when the ACT haplotype is present compared to when the ACT haplotype is absent (0.539 times the hazard). c Hazard ratio = 0.543 indicates the hazard of relapse is lower when the rs33388 T allele is present compared to when the rs33388 T allele is absent (0.543 times the hazard). d Hazard ratio = 1.92 indicates that the hazard of relapse is 1.92 times higher when the ACA haplotype is present compared to when the ACA haplotype is absent.
TA B L E 3 Significant associations between relapse and (a) the presence/ absence of GR SNP variables in the training set for the recipient; (b) the presence of the ACA haplotype in the recipient GCR in the validation set F I G U R E 3 Cumulative incidence of relapse. (a) For GR haplotype ACT in the first cohort, the black line corresponds to the absence of the ACT haplotype in the recipient and the grey line its presence (Gray's test, p = 0.026, cumulative incidence at 2 years for ACT present: 0.245, 95% CI: 0.187-0.308; cumulative incidence at 2 years for ACT absent: 0.400, 95% CI: 0.284-0.512). (b) For GR haplotype ATA in the first cohort, the black line corresponds to the absence of the ATA haplotype in the recipient and the grey line its presence (Gray's test, p = 0.037, cumulative incidence at 2 years for ATA present: 0.378, 95% CI: 0.272-0.483; cumulative incidence at 2 years for ATA absent: 1.044-3.880), in the first cohort a trend for this association was also observed. These results strengthen our hypothesis that the presence of SNPs which incur GC resistance induce more cGvHD and hence more GVL following myeloablative conditioning. There is a well-documented association between the occurrence of cGvHD and reduced relapse risk in HSCT, Signori et al. (2012) so this could explain our findings in the first patient cohort and the reanalysed cohort which received myeloablative conditioning. In patients undergoing myeloablative conditioning therapy, carriage of the T allele rs33388 could exert its effect in the recipient in the first phase (cytokine storm) of GvHD/GvL induction, Nestel, Price, Seemayer, and Lapp (1992) . Interestingly in both the first cohort and myeloablative conditioning cohort, none of the variables were significant for incidence and severity of aGvHD.
Conversely for the RIC cohort (n = 252), the presence of the T allele of rs33388 and the ACT haplotype in the donor were found to be associated with reduced OS, (p = 0.025, HR: 1.659, 95% CI: 
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